Abstract. Point mutations of KRAS and BRAF genes are thought to be important in carcinogenesis of colon cancer. In particular, gene instability caused by decreased expression of the hMLH1 gene, a DNA mismatch repair (MMR) gene, may be linked to the activating BRAF V600E point mutation in sporadic colon cancer. However, a consensus has not been established regarding the correlation between point mutations of KRAS or BRAF and carcinogenesis in patients with endometrial cancer, which is closely related to colon cancer. Therefore, we analyzed aberrant hypermethylation of the hMLH1 gene, microsatellite instability (MSI), and point mutations of KRAS and BRAF in 44 samples of sporadic endometrial cancer, with the aim of examining the mechanism of carcinogenesis in patients with endometrial cancer. Aberrant hMLH1 hypermethylation was found in 17 of the 44 cases (38.6%) and showed a significant positive correlation with MSI (p=0.02). This suggests that an abnormal MMR mechanism plays an important role in carcinogenesis of sporadic endometrial cancer. Point mutation of KRAS was found in 6 of the 44 cases (13.6%), but no BRAF V600E mutation was detected. These data suggest that the BRAF V600E mutation is not the target gene for abnormal MMR in carcinogenesis in patients with sporadic endometrial cancer, unlike in colon cancer. This is supported by the relatively few previous reports indicating a correlation between endometrial cancer and the BRAF V600E mutation. Identification of new candidates for the target gene for abnormal MMR in endometrial cancer requires further work.
Introduction
A cancer may develop as a result of repeated mutation of genes involved in differentiation or proliferation. Such a multistep mechanism of carcinogenesis with mutation of multiple cancer-related genes is often observed in patients with colon cancer. The correlation between colon cancer carcinogenesis and point mutation of RAS/RAF genes in the MAP kinase pathway suggests that these genes have an important role at an early stage of malignant alteration of colon cancer (1) .
Endometrial cancer has many similarities with colon cancer and is detected at high rates as a double cancer of hereditary non-polyposis colon cancer (HNPCC). Germline mutation of hMLH1, a DNA mismatch repair (MMR) gene, occurs at high rates in HNPCC patients (2) , and decreased expression of hMLH1 due to aberrant hypermethylation has also been found in patients with sporadic colon cancer and endometrial cancer (3) . Decreased expression of hMLH1 due to epigenetic changes may facilitate gene replication errors and cause gene instability, which can be detected as microsatellite instability (MSI) (4) . Microsatellite DNA is a region with short repeated sequences of 1-2 bases, and PCR-based detection of replication errors in this region has been used widely as a clinical test to examine gene instability. Such instability may cause mutation of cancerrelated genes, and a correlation between MSI due to decreased hMLH1 expression and point mutations of KRAS and BRAF genes has been proposed in patients with colon cancer (5, 6) .
Mutation of the BRAF gene has been found in many human cancers, including colon cancer, malignant melanomas, thyroid carcinoma and ovarian carcinoma (7) (8) (9) . BRAF is one of the 3 subtypes of RAF family genes and encodes a tyrosine kinase involved in mitogenic signaling in the RAS-RAF-MEK-ERK-MAP kinase pathway. The function of RAF is regulated by RAS, and an activating point mutation of BRAF causes unregulated constitutive activation of the tyrosine kinase activity and facilitates cell proliferation via the MAP kinase pathway. The V600E mutation in exon 15 of BRAF is of particular interest, since tyrosine kinase activity 10-fold that of wildtype has been found in tumor tissue with this mutation (10) . The V600E mutation is found in about 15% of patients with sporadic colon cancer and can be used for clinical diagnosis of non-inheritive sporadic colon cancer (10) . Furthermore, since BRAF V600E is observed in 32% of cases of MSI-positive sporadic colon cancer and 75% of cases with sporadic colon cancer with aberrant hypermethylation of hMLH1, BRAF has been proposed as the target gene of abnormal MMR (11) .
In contrast to colon cancer, only a few reports have shown mutation of BRAF in patients with endometrial cancer. Feng et al found BRAF mutations in 21% of patients with endometrial cancer and suggested that the mutation correlated with decreased hMLH1 expression (12) . However, Salvesen et al found a BRAF mutation in only 2% of patients with endometrial cancer (13) . Therefore, it is unclear whether mutation of BRAF is important in carcinogenesis of endometrial cancer and whether the mutation may be linked to abnormal expression of the hMLH1 gene. In this study, we analyzed aberrant hypermethylation of hMLH1, MSI, and mutations of KRAS and BRAF in patients with sporadic endometrial cancer to examine correlations among point mutations in RAS/RAF family genes, abnormal MMR caused by aberrant hMLH1 hypermethylation, and carcinogenesis of sporadic endometrial cancer.
Materials and methods
Cell lines. Eight cell strains were used in the study: HEC108, Ishikawa (a human endometrial cancer-derived cultured cell line supplied by Dr Hiroyuki Kuramoto); HOOUA and HHUA (supplied by Dr Isamu Ishiwata); and SNG-II, SNG-M, HEC-1B and KLE. KLE cells were cultured in a DMEM/F12 (1:1) medium (Gibco-BRL, Rockville, MD, USA) supplemented with 10% fetal bovine serum (FBS) (Sanko Junyaku Co., Tokyo, Japan). All other cells were cultured in 10% FBSsupplemented F12 medium (Sigma, St. Louis, MO, USA). The cells were incubated in a dish of 10 cm in diameter under 5% CO 2 at 37˚C.
Clinical specimens. The subjects were 44 patients with endometrial cancer (G1, 20; G2, 11; G3, 13) who gave informed consent to collection of cancer specimens. Of these patients, 37 had endometrioid adenocarcinoma and 7 had adenosquamous carcinoma. The grade of histological differentiation (G1-G3) and the cancer stage at surgery were determined based on the Guidelines for Endometrial Cancer published by the Japan Society of Obstetrics and Gynecology.
DNA extraction and methylation-specific PCR (MSP) in the hMLH1 promoter region. DNA was extracted from the 44 endometrial cancer specimens using liquid-based cytology with a Get Pure DNA Kit (Dojindo Molecular Technologies, Inc., Kumamoto, Japan). Distilled water was added to 1 μg of the extracted DNA up to a volume of 50 μl and 5.5 μl of 3 N NaOH solution was added. After mixing, the solution was incubated at 37˚C for 15 min, and then 520 μl of 3 M sodium bisulfite (Sigma) prepared at pH 5.5 with 30 μl of 10 mM hydroquinone (Sigma) and 10 N NaOH was added to the solution. After mixing in an upturned position to prevent vaporization, the solution was overlaid with mineral oil and incubated at 50˚C overnight. Next, 1 ml of clean-up resin (Promega, Madison, WI, USA) was added to the lower layer and the resulting solution was mixed in an upturned position and then injected into a column. The column was rinsed with 2 ml of 80% isopropanol and then centrifuged at 15,000 rpm for 3 min to remove the isopropanol completely. Next, 50 μl of distilled water (70˚C) was added directly to the column, which was then centrifuged at 15,000 rpm for 2 min to extract DNA adsorbed on the column. Then, 5.5 μl of 2 N NaOH was added to the resulting DNA solution. After mixing, the solution was incubated at 37˚C for 20 min, after which 66 μl of 5 N ammonium acetate solution and 243 μl of 95% ethanol were added and the solution was incubated at 80˚C for 1 h and centrifuged at 15,000 rpm for 30 min to precipitate DNA. Approximately 50 μl of the supernatant was left in the tube. The rest of the supernatant was collected, mixed with 1 ml of 70% ethanol, and then centrifuged at 15,000 rpm for 30 min to rinse the DNA. The precipitated DNA was air-dried and dissolved in 20 μl of distilled water; 2 μl of this solution was used as the MSP template solution. AmpliTaq Gold and 10X PCR buffer/MgCl 2 with dNTP (Applied Biosystems, Foster City, CA, USA) was used in PCR analysis and DNA was analyzed using a GeneAmp PCR System 9700 (Applied Biosystems). The PCR primer sequences are shown in Table I . DNA extracted from the cultured cell lines was also used in MSP analysis of hMLH1 (14) .
Microsatellite instability analysis. Genomic DNA extracted from normal and tumor tissue samples from the 44 patients with endometrial cancer was PCR amplified at the microsatellite repeat loci D2S123, D5S346, D17S250, BAT26, BAT25, MSH3, MSH6, TGF-ßRII, BAX, MBD4A10 and MBD4A6, which include 3 dinucleotide (CA) and 8 mononucleotide repeats as microsatellite markers. PCR reactions were performed in a total volume of 25 μl containing 10X buffer, 0.125 mM deoxynucleoside triphosphate, 0.2 μM of each primer, and 0.25 units of TaqDNA polymerase. The PCR Table I . Primer sequences used in PCR and MSP analysis. 
conditions were as follows: 94˚C for 10 min; 30 cycles at 94˚C for 45 sec, 58˚C for 45 sec, and 72˚C for 40 sec; followed by a final extension step at 72˚C for 10 min. After PCR, 1 μl of the product was mixed with 12 μl of loading buffer containing formamide and Rox size standards. This mixture was denatured at 95˚C for 2 min and cooled on ice before loading onto an ABI PRISM 310 sequencer (Applied Biosystems). The results were analyzed using GeneScan software (Applied Biosystems).
Tumors were classified as MSI-H when ≥30% of these markers showed MSI, in accordance with the recent recommendation of the National Cancer Institute Workshop. Low-frequency MSI (<30% of 11 markers) was included in the category of MSI-L and alteration of even one microsatellite region led to definition of the patient as MSI-positive (15) .
Determination of KRAS and BRAF mutations. DNA was extracted from the 8 endometrial cancer-derived cell lines and 44 endometrial cancer specimens using liquid-based cytology with a Get Pure DNA Kit (Dojindo Molecular Technologies). Individual point mutations of the KRAS and BRAF genes were documented using two gene-specific oligonucleotide primer pairs designed for PCR amplification of the region of the KRAS gene harboring codons 12 and 13 and the region of exon 15 of the BRAF gene encompassing codon 600, respectively. The oligonucleotide primers for sequencing of KRAS and BRAF are shown in Table I . Each exon was amplified by PCR using 0.5 Ag of template DNA, sense and antisense primers, and an AmpliTaq Gold PCR kit (Applied Biosystems). A total of 50 μl of reaction mixture was prepared according to the manufacturer's instructions and PCR was commenced at 94˚C for 3 min; followed by 35 cycles of 94˚C for 30 sec, 64˚C or 60˚C for 30 sec, and 72˚C for 1 min; with a final extension step for 5 min. The PCR products were purified using an UltraClean PCR Clean-up kit (Mobio Laboratories, Solana Beach, CA) and subjected to direct sequencing using purified products and the same sets of primers in a capillary automatic sequencer (ABI PRISM 3100 Genetic Analyzer, Applied Biosystems). Sequence data were analyzed using the Basic Local Alignment Search Tool (BLAST) software located at the National Center for Biotechnology Information web site (http://www.ncbi.nlm.nih.gov) (12) .
Statistical analysis. Correlation of KRAS mutations with the grade of histological differentiation and the cancer stage at surgery were analyzed using the ¯2 test and Mann-Whitney test, respectively. Correlation of KRAS mutations with patient age was also examined, after establishing that age had a normal distribution in the groups of patients with and without KRAS mutations. Mann-Whitney test was used to examine whether the population medians of the two independent groups differed significantly. Correlation of aberrant DNA hypermethylation of hMLH1 with MSI was analyzed by the ¯2 test.
Results
MSP analysis of samples of endometrial cancer showed aberrant hMLH1 hypermethylation in 17 of the 44 cases (38.6%) (Fig. 1 , Table II ). In MSI analysis, 31.8% (14 samples), 6.8% (3 samples), and 61.4% (27 samples) of the cases were categorized as MSI-H, MSI-L and MSS (microsatellite stability), respectively; that is, 38.6% were judged to be MSI-positive. Aberrant hypermethylation of the hMLH1 gene was found in a higher number of MSI-positive cases, with a statistically significant positive correlation (p=0.02) between abnormal hMLH1 methylation and MSI (Table III) .
A point mutation at codon 12 of KRAS was found in 3 (HEC-1B, HHUA and SNG-M) of the 8 endometrial cancerderived cell lines that were examined. These changes resulted in a G-D mutation in one cell line and G-V mutations in the other 2 cell lines. None of the cell lines had a point mutation at codon 13 of KRAS or at codon 600 of BRAF (Table IV) . A point mutation at codon 12 of KRAS was observed in 6 of the 44 samples of endometrial cancer (13.6%) (Fig. 2 , Table II) , with a similar mutation to those in the cultured cell lines (G-D or V) in 5 of the 6 cases (83.3%). The point mutation at codon 12 of KRAS showed no correlation with clinicopathological characteristics of endometrial cancer or with age upon development of cancer, but tended to occur more frequently in well-differentiated adenocarcinoma (p=0.1, Table V ). There were no correlations among aberrant hMLH1 hypermethylation, MSI, and point mutation at codon 12 of KRAS. No point mutation at codon 13 of KRAS (Table II) or at codon 600 of BRAF (Table VI) was found in the 44 clinical samples of endometrial cancer.
Discussion
Carcinogenesis of colon cancer has been correlated with point mutation of the RAS/RAF family of genes in the MAP kinase pathway, suggesting the importance of mutation of these genes in an early stage of malignant change in colon cancer (1) . Since mutations of KRAS and BRAF are observed in many MSI-positive cases of sporadic colon cancer with aberrant hypermethylation of the hMLH1 gene, a correlation with MSI caused by decreased expression of hypermethylated hMLH1 has been suggested (5). Similar decreased expression of hMLH1 due to aberrant hypermethylation has been reported in endometrial cancer (14) , but the correlation with point mutations of KRAS and BRAF remains unclear.
In the present study, aberrant hypermethylation of hMLH1 was found in 38.7% of cases of sporadic endometrial cancer. Expression of hMLH1 is significantly reduced by aberrant hypermethylation (14) and this may induce gene instability that can be detected as microsatellite instability (MSI). Previous studies have shown that about 13% of cases of sporadic colon cancer are MSI-positive (16) Table III . Correlation between MSI and abnormal hypermethylation of the hMLH1 gene in cases of endometrial cancer.
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MSI, microsatellite instability; MSS, microsatellite stability; M, methylated; U, unmethylated.
- Table IV . KRAS and BRAF gene mutations in human endometrial cancer-derived cell lines.
Codon 13 Codon 600 
Statistical analysis was performed with the ¯2 test and Mann-Whitney test. Mut, mutation; Wt, wild-type.
- Table VI . Correlation of abnormal BRAF V600E genes with abnormal MMR and mutated KRAS genes. -
------------------------------------------------
MSI, microsatellite instability; M, methylated; U, unmethylated; Mut, mutation; Wt, wild-type.
- (18) . In our analysis, point mutation at codon 12 was confirmed in 14% of cases, but none were observed at codon 13 and KRAS mutation showed no correlation with age. The incidence of well-differentiated adenocarcinoma tended to be high among cases with a mutation of KRAS, but the relationship was not significant, and there was no tendency for a higher rate of mutation of KRAS in MSI-positive cases. Point mutation of KRAS has been found in 51% of cases with colon cancer, and the rate in endometrial cancer is much lower (1) . Mutation of KRAS may have some correlation with carcinogenesis in patients who develop sporadic endometrial cancer at an old age, but the current and previous results suggest that this mutation is not important for carcinogenesis in other cases of sporadic endometrial cancer.
Feng et al found mutation of the BRAF gene in 21% of cases of endometrial cancer, and proposed a correlation with decreased expression of the MMR gene (12) . In contrast, Salvesen et al found the activating BRAF V600E mutation in only 2% of cases of endometrial cancer, and a consensus has not been obtained regarding the correlation between carcinogenesis of endometrial cancer and BRAF mutation (13) . In our analysis, no BRAF V600E mutation was observed in cases of sporadic endometrial cancer. Collectively, these data suggested that the BRAF V600E mutation occurs at an extremely low rate in endometrial cancer, and thus may not be important for carcinogenesis of sporadic endometrial cancer. In contrast, the BRAF V600E mutation occurs at a high rate in sporadic colon cancer, and may be useful diagnostically to rule out the possibility of a hereditary tumor. However, this mutation is not useful in diagnosis of sporadic endometrial cancer.
Since we did not find a BRAF V600E mutation in our analysis, there was clearly no correlation between the BRAF V600E mutation and aberrant hypermethylation of hMLH1 or MSI. Decreased expression of hMLH1 due to aberrant hypermethylation could cause gene instability, with a high rate of mutation of a target gene such as BRAF. However, our results suggest that BRAF is not the target of abnormal MMR in sporadic endometrial cancer. On the other hand, since aberrant hypermethylation of hMLH1 and MSI were detected at high rates in sporadic endometrial cancer patients, an abnormal MMR system is clearly associated with the mechanism of carcinogenesis in endometrial cancer. Identification of the new target gene for abnormal MMR will be extremely important for clarification of this mechanism.
